Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High – What’s Next?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $37.35 and last traded at $36.2480, with a volume of 22298869 shares. The stock had previously closed at $35.52.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Scotiabank boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Teva Pharmaceutical Industries Stock Up 2.0%

The firm has a market capitalization of $41.58 billion, a PE ratio of 30.21, a PEG ratio of 2.02 and a beta of 0.70. The business’s fifty day moving average price is $30.93 and its 200 day moving average price is $23.53. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 77,400 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the sale, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. This represents a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 622,060 shares of company stock worth $17,076,965 over the last three months. 0.55% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 51.4% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after buying an additional 11,334,780 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its position in shares of Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after acquiring an additional 9,303,978 shares during the period. Phoenix Financial Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after acquiring an additional 9,094,372 shares in the last quarter. Soundwatch Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $143,533,000. Finally, Wellington Management Group LLP grew its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.